Amitriptyline and Vepdegestrant: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Amitriptyline
Vepdegestrant
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both of your medicines can affect your heart's electrical timing, something called the QT interval. Amitriptyline (Elavil) is an older antidepressant known to do this, and vepdegestrant (Veppanu), your cancer medicine, can too. When taken together, that effect can add up and, in rare cases, lead to a dangerous fast or irregular heartbeat.
This is based mostly on how these drugs are expected to behave, not a lot of real-world reports, but it's still worth taking seriously. The good news is your care team can manage this. Please don't stop either medicine on your own. Let your doctor or pharmacist know you take both so they can decide the safest plan and watch your heart closely.
Effect: Additive QTc prolongation with increased risk of torsade de pointes, polymorphic VT, and other serious arrhythmias.
Mechanism: Pharmacodynamic additive QT prolongation. Both agents independently prolong the QTc; neither is a prodrug and the interaction is not metabolic. Evidence: theoretical. Onset: unspecified.
Management:
- Avoid concomitant use where possible.
- If unavoidable, obtain baseline and on-treatment ECGs; monitor as clinically indicated.
- Correct reversible causes (hypokalemia, hypomagnesemia).
- Per labeling, withhold vepdegestrant for QTc >480 ms or >60 ms rise; reduce dose or discontinue per QTc thresholds; permanently discontinue if torsade/serious arrhythmia occurs.
What happens
An increased risk of QT interval prolongation and an increased risk of torsade de pointes, polymorphic ventricular tachycardia, other serious arrhythmia symptoms
Interaction Deep Dive
Vepdegestrant should not be given together with other agents recognized as capable of prolonging the QTc interval, because doing so can produce a larger rise in QTc and provoke adverse events tied to QTc prolongation, such as torsade de pointes, additional serious arrhythmias, and sudden death. When concurrent use is unavoidable, perform ECGs at the start of the combined therapy, throughout its duration, and whenever clinically warranted. For patients whose QTc exceeds 480 ms or rises more than 60 ms over baseline (while remaining at or below 500 ms): hold vepdegestrant until the QTc returns to 480 ms or below and is no more than 60 ms above baseline. Address correctable contributors (for example, hypokalemia and hypomagnesemia), and then restart vepdegestrant at the same dose. Institute more frequent ECG monitoring. For patients whose QTc exceeds 500 ms: hold vepdegestrant until the QTc is at or below 480 ms and less than 60 ms above baseline. When a reversible cause is found and corrected, restart vepdegestrant at the same dose; if no reversible cause is found, restart vepdegestrant at a lowered dose. Increase how often ECGs are monitored, and permanently stop vepdegestrant if QTc greater than 500 ms happens again. For patients who develop torsade de pointes, polymorphic ventricular tachycardia, or symptoms of serious arrhythmia: permanently discontinue vepdegestrant1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Both drugs can lengthen the heart's QT interval, so the effect may add together. Here is what typically happens and what you can do:
- Keep taking both medicines as prescribed unless your doctor tells you otherwise.
- Your team may order an ECG (heart tracing) before and during treatment to keep an eye on things.
- They may check and correct blood minerals like potassium and magnesium, which affect heart rhythm.
- The vepdegestrant dose may need to be adjusted and individualized by your care team, and they may monitor you more closely.
Call your doctor right away if you feel fainting, dizziness, a racing or irregular heartbeat, or palpitations. Ask your pharmacist before starting any new medicine.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Amitriptyline and Vepdegestrant together?
Taking amitriptyline and vepdegestrant together can add up to prolong the QT interval and raise the risk of dangerous heart rhythms. Don't stop either drug on your own, but tell your care team so they can monitor your heart (ECGs) and adjust treatment as needed. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Amitriptyline and Vepdegestrant interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Amitriptyline and Vepdegestrant interaction managed?
Both drugs can lengthen the heart's QT interval, so the effect may add together. Here is what typically happens and what you can do: Keep taking both medicines as prescribed unless your doctor tells you otherwise. Your team may order an ECG (heart tracing) before and during treatment to keep an eye on things. They may check and correct blood minerals like potassium and magnesium, which affect hear… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Amitriptyline or Vepdegestrant need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VEPPANU oral tablet, vepdegestrant oral tablet. Pfizer Inc. New York, NY, 2026. DailyMed
Keep reading about Amitriptyline
Keep reading about Vepdegestrant
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist